Overview

Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI

Status:
Active, not recruiting
Trial end date:
2021-10-30
Target enrollment:
0
Participant gender:
Female
Summary
In a prospective cohort study investigators will examine characteristics and clinical outcomes of treatment with ART in women with tubal factor infertility (TFI) with regard to seropositivity to antichlamydial antibodies.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
Treatments:
Antibodies
Immunoglobulins
Criteria
Inclusion Criteria:

- Tubal factor infertility diagnosed by laparoscopy;

- Female age between 20-41 years;

- BMI 17,5-35 kg/m2;

- Early follicular phase follicle stimulating hormone (FSH) ≤15 IU/L

- Presence of viable spermatozoa in partner's sperm;

- Signed informed consent.

Exclusion Criteria:

- previous ovarian surgery;

- endometriosis;

- antimullerian hormone (AMH) level ≤0,3 ng/ml;

- hyper- or hypogonadotropic ovarian failure;

- severe male factor infertility;

- Pre-existing medical condition preventing or interfering with IVF treatment: any
clinically significant systemic disease; inherited or acquires thrombophilia and
thromboembolism; endocrine or metabolic abnormalities; moderate or severe impairment
of renal or hepatic function; any oncological diseases in anamnesis; known history of
recurrent miscarriage, abnormal karyotype of both partners; currently active pelvic
inflammatory disease;

- Abnormal IVF screening tests: Papanicolaou (PAP) smear, Syphilis, HIV 1&2, Hepatitis
B, Hepatitis C, Chlamydia, and Gonorrhea;

- Presence of uterine pathology: Asherman's Syndrome, endometrial polyps, nodus form of
adenomyosis or uterine fibroids ≥3 mm in diameter;

- Visualization of ovarian cysts ≥25 mm, endometriomas or hydrosalpinx;

- One or more follicles ≥8 mm at the start of the COS protocol.